BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
155.9 EUR
+2.35 (+1.53%)
Overall IDP gets a fundamental rating of 5 out of 10. We evaluated IDP against 81 industry peers in the Biotechnology industry. While IDP has a great health rating, its profitability is only average at the moment. IDP has a bad growth rate and is valued cheaply. This makes IDP very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year IDP was profitable.
In the past year IDP had a positive cash flow from operations.
IDP had positive earnings in each of the past 5 years.
Each year in the past 5 years IDP had a positive operating cash flow.
1.2 Ratios
IDP has a Return On Assets of 5.51%. This is in the better half of the industry: IDP outperforms 79.01% of its industry peers.
IDP has a Return On Equity of 8.84%. This is amongst the best in the industry. IDP outperforms 80.25% of its industry peers.
The Return On Invested Capital of IDP (9.70%) is better than 86.42% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IDP is below the industry average of 13.22%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
With an excellent Profit Margin value of 15.98%, IDP belongs to the best of the industry, outperforming 81.48% of the companies in the same industry.
In the last couple of years the Profit Margin of IDP has declined.
IDP has a better Operating Margin (28.50%) than 87.65% of its industry peers.
IDP's Operating Margin has declined in the last couple of years.
IDP's Gross Margin of 75.24% is fine compared to the rest of the industry. IDP outperforms 65.43% of its industry peers.
IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IDP is creating some value.
Compared to 1 year ago, IDP has more shares outstanding
Compared to 5 years ago, IDP has less shares outstanding
The debt/assets ratio for IDP has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.35 indicates that IDP is not in any danger for bankruptcy at the moment.
IDP's Altman-Z score of 3.35 is fine compared to the rest of the industry. IDP outperforms 72.84% of its industry peers.
IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.78, IDP is in the better half of the industry, outperforming 79.01% of the companies in the same industry.
A Debt/Equity ratio of 0.35 indicates that IDP is not too dependend on debt financing.
IDP has a Debt to Equity ratio of 0.35. This is comparable to the rest of the industry: IDP outperforms 48.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.35 |
ROIC/WACC1.18
WACC8.2%
2.3 Liquidity
IDP has a Current Ratio of 2.72. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.72, IDP is in line with its industry, outperforming 55.56% of the companies in the same industry.
IDP has a Quick Ratio of 2.04. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IDP (2.04) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.51% over the past year.
Measured over the past years, IDP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
Looking at the last year, IDP shows a small growth in Revenue. The Revenue has grown by 4.77% in the last year.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
Based on estimates for the next years, IDP will show a small growth in Earnings Per Share. The EPS will grow by 0.56% on average per year.
IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.63% yearly.
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.56%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.63%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.86, the valuation of IDP can be described as reasonable.
92.59% of the companies in the same industry are more expensive than IDP, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.41, IDP is valued rather cheaply.
IDP is valuated reasonably with a Price/Forward Earnings ratio of 11.65.
Based on the Price/Forward Earnings ratio, IDP is valued cheaper than 97.53% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.40, IDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.86 | ||
| Fwd PE | 11.65 |
4.2 Price Multiples
87.65% of the companies in the same industry are more expensive than IDP, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 92.59% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.79 | ||
| EV/EBITDA | 7.98 |
4.3 Compensation for Growth
IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
5. Dividend
5.1 Amount
IDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IDP (12/4/2025, 7:00:00 PM)
155.9
+2.35 (+1.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap22.87B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.81
Price Target154.93 (-0.62%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)4.58%
PT rev (3m)5.78%
EPS NQ rev (1m)-53.66%
EPS NQ rev (3m)-54.42%
EPS NY rev (1m)-3.62%
EPS NY rev (3m)-4.16%
Revenue NQ rev (1m)-2.43%
Revenue NQ rev (3m)-2.17%
Revenue NY rev (1m)0.92%
Revenue NY rev (3m)0.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.86 | ||
| Fwd PE | 11.65 | ||
| P/S | 2.65 | ||
| P/FCF | 11.79 | ||
| P/OCF | 10.87 | ||
| P/B | 1.47 | ||
| P/tB | 11.19 | ||
| EV/EBITDA | 7.98 |
EPS(TTM)14.35
EY9.2%
EPS(NY)13.38
Fwd EY8.59%
FCF(TTM)13.22
FCFY8.48%
OCF(TTM)14.34
OCFY9.2%
SpS58.82
BVpS106.39
TBVpS13.94
PEG (NY)N/A
PEG (5Y)N/A
Graham Number185.34
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.35 |
F-Score5
WACC8.2%
ROIC/WACC1.18
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.56%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
Can you provide the valuation status for BIOGEN INC?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for IDP stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
Can you provide the expected EPS growth for IDP stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -5.79% in the next year.